Lucy Therapeutics
John is the Global Head of Integrated Drug Discovery at Sanofi. He has 35 years of drug discovery experience in big pharma with 20 years in CNS. He was the Chair of the MEDI Division of the ACS in 2015 and the co-inventor of two marketed drugs (Relpax® and Nurtec®) and several other clinical candidates (including sparsentan, zavegepant and LX-9211 currently in late clinical trials). John was inducted into the ACS MEDI Hall of Fame in 2014.
This person is not in the org chart
This person is not in any offices
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.